51 related articles for article (PubMed ID: 38730287)
21. Body motion detection and correction in cardiac PET: Phantom and human studies.
Sun T; Petibon Y; Han PK; Ma C; Kim SJW; Alpert NM; El Fakhri G; Ouyang J
Med Phys; 2019 Nov; 46(11):4898-4906. PubMed ID: 31508827
[TBL] [Abstract][Full Text] [Related]
22. Dynamic whole-body PET imaging: principles, potentials and applications.
Rahmim A; Lodge MA; Karakatsanis NA; Panin VY; Zhou Y; McMillan A; Cho S; Zaidi H; Casey ME; Wahl RL
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):501-518. PubMed ID: 30269154
[TBL] [Abstract][Full Text] [Related]
23. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
24. Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic
Meijer TWH; de Geus-Oei LF; Visser EP; Oyen WJG; Looijen-Salamon MG; Visvikis D; Verhagen AFTM; Bussink J; Vriens D
Radiology; 2017 May; 283(2):547-559. PubMed ID: 27846378
[TBL] [Abstract][Full Text] [Related]
25. The Eighth Edition Lung Cancer Stage Classification.
Detterbeck FC; Boffa DJ; Kim AW; Tanoue LT
Chest; 2017 Jan; 151(1):193-203. PubMed ID: 27780786
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.
Deppen SA; Blume JD; Kensinger CD; Morgan AM; Aldrich MC; Massion PP; Walker RC; McPheeters ML; Putnam JB; Grogan EL
JAMA; 2014 Sep; 312(12):1227-36. PubMed ID: 25247519
[TBL] [Abstract][Full Text] [Related]
27. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
28. Low dose interpolated average CT for thoracic PET/CT attenuation correction using an active breathing controller.
Sun T; Wu TH; Wang SJ; Yang BH; Wu NY; Mok GS
Med Phys; 2013 Oct; 40(10):102507. PubMed ID: 24089928
[TBL] [Abstract][Full Text] [Related]
29. Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy?
Sabbatino F; Ferrone S
Clin Cancer Res; 2013 Mar; 19(5):958-60. PubMed ID: 23340298
[TBL] [Abstract][Full Text] [Related]
30. Going beyond EGFR.
Zimmermann S; Peters S
Ann Oncol; 2012 Sep; 23 Suppl 10():x197-203. PubMed ID: 22987962
[TBL] [Abstract][Full Text] [Related]
31. Solitary pulmonary nodules differentiated by dynamic F-18 FDG PET in a region with high prevalence of granulomatous disease.
Huang YE; Lu HI; Liu FY; Huang YJ; Lin MC; Chen CF; Wang PW
J Radiat Res; 2012; 53(2):306-12. PubMed ID: 22374400
[TBL] [Abstract][Full Text] [Related]
32. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
33. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
34. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease.
Deppen S; Putnam JB; Andrade G; Speroff T; Nesbitt JC; Lambright ES; Massion PP; Walker R; Grogan EL
Ann Thorac Surg; 2011 Aug; 92(2):428-32; discussion 433. PubMed ID: 21592456
[TBL] [Abstract][Full Text] [Related]
35. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
36. Joint correction of respiratory motion artifact and partial volume effect in lung/thoracic PET/CT imaging.
Chang G; Chang T; Pan T; Clark JW; Mawlawi OR
Med Phys; 2010 Dec; 37(12):6221-32. PubMed ID: 21302779
[TBL] [Abstract][Full Text] [Related]
37. Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area.
Sathekge MM; Maes A; Pottel H; Stoltz A; van de Wiele C
S Afr Med J; 2010 Sep; 100(9):598-601. PubMed ID: 20822650
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Mok TS; Wu YL; Thongprasert S; Yang CH; Chu DT; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; Yang JJ; Chewaskulyong B; Jiang H; Duffield EL; Watkins CL; Armour AA; Fukuoka M
N Engl J Med; 2009 Sep; 361(10):947-57. PubMed ID: 19692680
[TBL] [Abstract][Full Text] [Related]
39. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Huang CT; Yen RF; Cheng MF; Hsu YC; Wei PF; Tsai YJ; Tsai MF; Shih JY; Yang CH; Yang PC
Med Oncol; 2010 Mar; 27(1):9-15. PubMed ID: 19130320
[TBL] [Abstract][Full Text] [Related]
40. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
